<DOC>
	<DOCNO>NCT00762567</DOCNO>
	<brief_summary>To characterize pharmacokinetics phenylephrine two pediatric population : child , age 2 &lt; 12 year , adolescent , age 12 &lt; 18 year .</brief_summary>
	<brief_title>Phenylephrine Pediatric Pharmacokinetic Study</brief_title>
	<detailed_description>This study open-label , single-dose classical pharmacokinetic design comparator treatment group . At least twenty-four ( 24 ) child , age 2 &lt; 12 year , twelve ( 12 ) adolescent , age 12 &lt; 18 year , nasal symptom due hay fever upper respiratory allergy complete study . To ensure young child represent , least 35 % ( 8 ) 24 child enrol range 2 &lt; 6 year age .</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Nasal Decongestants</mesh_term>
	<criteria>Male female child adolescent , age 2 &lt; 18 year , minimum weight 24 pound eligible participate . In addition , subject &gt; 5th percentile &lt; 95th percentile weight base age gender . Subjects body mass index ( BMI ) &gt; 5th percentile less equal 90th percentile age gender . Subjects history allergic rhinitis experience nasal symptom associate hay fever upper respiratory allergy include . Subjects parent legally authorize representative , investigator 's view , likely compliant complete study eligible participate . Post menarchal female subject must negative urine pregnancy test screen Visit 2 Day 1 study medication administer . Post menarchal female subject must practice abstinence use effective form birth control ( e.g. , intrauterine device , oral contraceptive , contraceptive implant injection , diaphragm spermicide , cervical cap , consort use condom ) least three month enrol study . Parents legally authorize representative sign date IRBapproved consent form subject participate study indicate subject ( and/or legally acceptable representative ) inform pertinent aspect study . Subjects , age 6 &lt; 18 year , provide write assent participate study Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic disease . Findings medical history physical examination vital sign measurement within range clinical acceptability . Have know sensitivity allergy phenylephrine EMLA cream . Took prescription nonprescription medication ( except vitamin and/or fluoride supplement ) within seven day study 's start date . Drank fruit juice ( i.e. , apple , orange , grapefruit ) within two day prior study start . Use monoamine oxidase inhibitor within two week prior dose phenylephrine . Participated , complete , another clinical trial within seven week study 's start date . Have history drug , alcohol , tobacco use ( old child adolescent ) . Have history hepatitis B , previous positive test hepatitis B surface antigen , previous positive hepatitis C antibody . Have history HIV infection previous demonstration HIV antibody . Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method nonhormonal contraception least three month prior first dose study medication completion followup procedure . Relationship person involve directly conduct study ( ie , principal investigator ; subinvestigators ; study coordinator ; study personnel ; employee contractor sponsor subsidiary ; family ) .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>